Investigational drug · Phase 3
TQC2731
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP).
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
3 still active
All registered trials
7
Any phase or sponsor naming "TQC2731"
First trial start
2022
Sep 23, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TQC2731", any sponsor or status.
Conditions studied
As listed on its trial records.
- Asthma
- Chronic Obstructive Pulmonary Disease
- Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- Severe Asthma
- Chronic Sinusitis
- Nasal Polyps
Approved drugs for the same conditions: Asthma · COPD · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "TQC2731" as an intervention, largest first.
- TQC2731 Clinical Trial for the Treatment of Severe Asthma With InjectionPivotal-lookingRecruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Industry
NCT06829784 · 660 participants (planned) · Start Mar 21, 2025 · Primary completion Dec 2027
Drug: TQC2731 injection; Placebo · For: Asthma
Sites: Bozhou, China; Hefei, China; Lu'an, China · 101 sites in all
- A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseasePivotal-lookingActive, not recruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Industry
NCT06707883 · 258 participants · Start Dec 31, 2024 · Primary completion Dec 2026
Drug: TQC2731 injection; TQC2731 Placebo · For: Chronic Obstructive Pulmonary Disease
Sites: Chuzhou, China; Hefei, China; Huainan, China · 60 sites in all
- Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal PolypsPivotal-lookingActive, not recruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Industry
NCT07107256 · 246 participants · Start Sep 25, 2025 · Primary completion Mar 2027
Drug: TQC2731 injection; Placebo of TQC2731 · For: Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Sites: Fuyang, China; Hefei, China; Beijing, China · 60 sites in all
- Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma.Pivotal-lookingCompleted
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT05472324 · 205 participants · Start Sep 23, 2022 · Primary completion Mar 5, 2025
Drug: TQC2731 injection; Placebo · For: Severe Asthma
Sites: Guangzhou, China; Zhengzhou, China
- Phase I Clinical Trial of TQC2731 InjectionStatus unknown
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT04923607 · 96 participants (planned) · Start Jun 25, 2021 · Primary completion Aug 25, 2023
Drug: TQC2731; Placebo · For: Asthma Severe Persistent Controlled
Sites: Henan, China
- A Clinical Study of TQC2731 Injection in the Treatment of Chronic Rhinosinusitis With Nasal PolypsCompleted
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06036927 · 80 participants · Start Dec 8, 2023 · Primary completion Feb 5, 2025
Drug: TQC2731 injection; TQC2731 matching placebo · For: Chronic Sinusitis; Nasal Polyps
Sites: Wuhu, China; Guangzhou, China; Jieyang, China · 16 sites in all
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT06451640 · 59 participants · Start Jul 4, 2024 · Primary completion Oct 17, 2025
Drug: 210mg of TQC2731 injection; 420mg of TQC2731 injection · For: Chronic Rhinosinusitis With Nasal Polyps
Sites: Zunyi, China; Cangzhou, China; Jingzhou, China · 16 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Beyond inhaled medications: precision medicine and biologic therapies targeting the IL-33/TSLP/type 2 axis in COPD.
Song GQ, Chen B, He TL, et al. · Front Immunol 2026
- Investigational thymic stromal lymphopoietin inhibitors for the treatment of asthma: a systematic review.
Rogliani P, Manzetti GM, Bettin FR, et al. · Expert Opin Investig Drugs 2024
Also in development for Asthma
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LunsekimigSAR443765Phase 39 trials
Sanofi · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps
- GSK5784283Phase 38 trials
GSK · Pulmonary Disease, Chronic Obstructive, Asthma, Nasal Polyps
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- SHR-1905Phase 36 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Asthma, Chronic Rhinosinusitis With Nasal Polyps, Moderate-to-severe Atopic Dermatitis
- TozorakimabMEDI3506Phase 36 trials
AstraZeneca · Chronic Obstructive Pulmonary Disease (COPD), Asthma, Viral Lung Infection and Acute Respiratory Failure
- BFFBFF MDI 320, BFF MDI 160Phase 34 trials
AstraZeneca · Asthma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.